Artrya
Healthcare Software · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3/88 Broadway L Ste 14A, Crawley, Wester...Phone Number
+61 864787816Website
www.artrya.comRevenue
$5.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
3
1
1
About Artrya
Artrya is working to solve the worlds largest cause of death heart disease. The company is using Artificial Intelligence to more accurately identify patients at risk of Coronary Artery Disease and guide clinicians in delivering more effective treatment.Explore more
Artrya Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Artrya your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Artrya, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Artrya has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Artrya launches new products
Click to see if Artrya had a recent Job posting/layoffs
Check out if Artrya is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Artrya recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Artrya has new funding data
Congratulate Masked Content for being promoted to Masked Content at Artrya
Recommended Actions
Find VP level buyers at Artrya
Find more new buyers
Compare Similar Companies to Artrya
Compare insights from companies similar to Artrya, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Artrya is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
Artrya is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about Artrya.
Artrya financials insights
Gather financial insights about Artrya, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Unspecified
$15M
Artrya Tech Stack
A closer look at the technologies used by Artrya
See more technologies
Most Recent Scoops
Project
, according to a high-level source in Legal, has completed initiatives related to data privacy within the last nine months.
Information Security, Data Management, Cyber Security, Security, Privacy, Regulations
Project
, according to a high-level source in Legal, is in the midst of initiatives related to corporate governance. Artrya is currently evaluating SAP GRC.
Governance
Project
, according to a high-level source in Legal, has completed initiatives related to case management software within the last nine months.
Clinical Systems, Software, Healthcare Technology
Project
, according to a high-level source in Legal, has completed initiatives related to security framework within the last nine months.
IT Audit / Compliance, Information Security, Infrastructure, Product Security, Cyber Security, Security
Project
Intellectual Property, Legal Affairs
Artrya News & Media
Artrya (ASX:AYA) Is Up 20.1% After Securing First Multi-Year U.S. Salix Hospital Deal
Earlier this month, medical technology firm Artrya announced a three-year commercial agreement for its Salix platform with U.S.-based Northeast Georgia Health System, carrying a minimum value of US$300,000 plus additional fee-per-scan revenue from Salix Coronary Plaque and Flow modules. This deal marks a meaningful step in Artrya’s push into the U.S. healthcare market, giving its Salix platform a real-world reference customer and a recurring revenue foothold. We’ll now examine how this...Artrya (ASX:AYA) Valuation Spotlight as Q1 2026 Earnings Call Approaches
Anticipation is building around Artrya (ASX:AYA) as the company prepares to release its Q1 2026 results. An earnings call is scheduled for October 29, 2025. Investors are watching closely for insights into financial performance and strategic direction. See our latest analysis for Artrya. Artrya's share price has surged 26.6% over the past month and 160% in the last quarter, reflecting renewed optimism as investors eye growth potential tied to its upcoming earnings call. For thoseWill an A$80 Million Raise and FDA Approval Reshape Artrya's (ASX:AYA) US Ambitions?
Artrya Limited recently completed an A$80 million follow-on equity offering to support the US launch of its FDA-approved Salix device for coronary plaque detection. This significant capital raising reflects strong investor enthusiasm for Artrya’s expansion plans and advances in AI-enabled cardiology diagnostics. We’ll explore how the successful funding round and FDA milestone shape Artrya’s investment narrative as it accelerates US market entry. Uncover the next big thing with financially...FDA clearance of Salix® Coronary Plaque module
Significantly expands U.S. commercial opportunity with ability to charge fees per scan assessed Investor Webinar - 11.30am AEST (9.30am AWST) on 22 August 2025 PERTH, Australia, Aug. 21, 2025 /PRNewswire/ -- Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company...
Read more news
Top Healthcare Software Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Artrya
Sign Up For FreeTo access detailed company insights
Artrya is working to solve the worlds largest cause of death heart disease. The company is using Artificial Intelligence to more accurately identify patients at risk of Coronary Artery Disease and guide clinicians in delivering more effective treatment.... Read More
